An official website of the United States government
Home
Name
Doxorubicin, liposome-encapsulated
Alternate Names
Abbreviations
None
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
712227, 620212
Primary Site
None
Histology
None
Remarks
DOXIL Injection received FDA approval February 4, 2013 for the treatment of ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy and also for AIDS-related Kaposi's sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy.
Feb. 2015: FDA granted Orphan Drug Designation to liposomal doxorubicin for the treatment of Ewing's sarcoma, a rare cancer that develops in or around children's bones.
Feb. 2015: FDA granted Orphan Drug Designation to liposomal doxorubicin for the treatment of Ewing's sarcoma, a rare cancer that develops in or around children's bones.
Coding
This drug should be coded
